Abstract

Background. Comparative study of clinical and immunological efficiency of systemic [with desloratadine (Aerius®, Bayer n=28)] and topical [with azelastin (Allergodil®, Meda Pharma) n=28] antihistamine single-agent treatment of persistent allergic rhinitis in primary school children (56 children from 6 to 11 years old) was carried out on the basis of monitoring the dynamics of nasal mucosa inflammatory biomarkers (IgE, sIgA, IL-4, IL-8, IL-13, IFN-y, TNFa). Materials and Methods. Questionnaires, selfmonitoring diaries with daily score-based assessment of the symptoms and the score of used pharmacologic agents, nasal discharge and touch smears of nasal cavity mucosa were used as investigative parameters in the study. The study was performed with the permission of the Biomedical Ethics Committee of the State Budgetary Educational Institution of Higher Professional Education «Pacific State Medical University» of the Ministry ofHealth of the Russian Federation. Results. A monthlong therapy with desloratadine enabled clinical control of the symptoms of mild and moderate persistent allergic rhinitis in primary school children in 92,8% of cases and allowed to stop local allergic inflammation intensity as was proved by increasing symptom-free number of days and the fact that symptomatic treatment was not required. The use of desloratadine in the course of the next three months ensured retention of the achieved control. Side and adverse effects in the given group were not registered.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call